Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its subsidiary, Huisheng Biopharmaceutical, received Investigational New Drug approval from China’s National Medical Products Administration for a new Semaglutide Injection for weight loss. This product, which has shown promise in reducing hunger and improving various health metrics, is the first of its kind to receive IND approval for weight management. Moreover, the product represents the largest single product in the global weight loss market, reflecting significant growth in sales.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
